Home › Compare › BLBRF vs ABBV
BLBRF yields 3.39% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, BLBRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BLBRF + ABBV for your $10,000?
Bloomberry Resorts Corporation, through its subsidiaries, develops, owns, and operates hotels, casinos, and integrated resorts in the Philippines and Korea. The company develops tourist facilities, such as casino-entertainment complexes with casino, hotel, retail and amusement areas, and themed development components. It also owns and operates the Solaire Resort & Casino, a hotel and gaming resort consists of slot machines, gaming tables, electronic table games, and specialty restaurants; hotel rooms, suites, and bayside villas; food and beverage outlets, including Chinese, Korean, and Japanese, and Italian restaurants, as well as international buffet/coffee shop, noodle shop, live entertainment lounge, food court, lobby bar, and lounge area; and multilevel parking building with parking slots, a spa and fitness center, and Bayview promenade. In addition, the company owns and operates the Sky Tower that consists of all-suite hotel; VIP gaming salons with gaming tables and slot machines; the bar for VIP patrons; meeting rooms with meeting facility, and boardrooms and pre-function area; a lyrical theater; the Waterside Restobar and Oasis Garden Café restaurants; shooting club with rifle shooting bays and pistol bays; and multi-level parking garage. Further, it operates Jeju Sun Hotel & Casino, including rooms, and gaming operation with tables and electronic gaming machines, as well as food and beverage outlets; and cruise terminals. The company is based in Paranaque City, the Philippines. Bloomberry Resorts Corporation is a subsidiary of Prime Strategic Holdings, Inc.
Full BLBRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.